Form 144 Filer Information UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK0001834021Filer CCCXXXXXXXIs this a LIVE or TEST Filing?Is LIVE INFORMATIONSubmission Contact InformationIs the second second

Name Phone E-Mail Address

144: Issuer Information

Name of Issuer SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Socuritios
Class A Common	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	12930	300622.5	51703412	06/24/2024	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Amount of Date you Nature of Name of Is Date Date of Nature of Class Acquired Acquisition Person from this Donor **Securities** Payment Payment *

4D Molecular Therapeutics, Inc. 001-39782 5858 Horton Street Suite 455 Emeryville CALIFORNIA 94608 1-510-505-2680 David Kirn

	Transaction	Whom Acquired	a Acquired A Gift?	Acquired	
Class A Common	Acquired as 02/10/2022 compensation Stock Options	Issuer	46	25	Compensation 06/24/2024 Cashless exercise / same-day sale
Class A Common	Acquired as 12/11/2023 compensation Stock Options	Issuer	83	05	Compensation 06/24/2024 Cashless exercise / same-day sale

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report **I**

144: Remarks and Signature

Remarks	The sales of shares set forth herein are made in connection with a selling plan dated $3/21/2024$, that is intended to comply with Rule 10b5-1(c).
Date of Notice	06/24/2024
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1 <i>ATTENTION:</i>	03/21/2024

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date. Signature Goldman Sachs & Co. LLC on behalf of David Kirn

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)